PURPOSE: The aim of this study is to quantify excess absolute risk (EAR) and excess relative risk (ERR) of secondary leukemia among a large population-based group of testicular cancer survivors. METHODS: We identified 42,722 1-year survivors of testicular cancer within 14 population-based cancer registries in Europe and North America (1943-2002). Poisson regression analysis was used to model EAR (per 100,000 person-years [PY]) and ERR of secondary leukemia. Cumulative risks were calculated using a competing risk model. RESULTS: Secondary leukemia developed in 89 patients (EAR = 10.8 per 100,000 PY, 95% confidence interval [CI] = 7.6-14.6; ERR = 1.6, 95%CI = 1.0-2.2). Statistically significantly elevated risks were observed for acute myeloid leukemia (AML) (EAR = 7.2, 95%CI = 4.7-10.2) and acute lymphoblastic leukemia (EAR = 1.3, 95%CI = 0.4-2.8). In multivariate analyses, AML risk was higher among patients whose initial management included chemotherapy compared to those receiving radiotherapy alone (p = 0.1). Excess cumulative leukemia risk was approximately 0.23% by 30 years after testicular cancer diagnosis. CONCLUSIONS: Although ERR of leukemia following testicular cancer is large, EAR and cumulative risk, which are better gauges of the population burden, are small.
PURPOSE: The aim of this study is to quantify excess absolute risk (EAR) and excess relative risk (ERR) of secondary leukemia among a large population-based group of testicular cancer survivors. METHODS: We identified 42,722 1-year survivors of testicular cancer within 14 population-based cancer registries in Europe and North America (1943-2002). Poisson regression analysis was used to model EAR (per 100,000 person-years [PY]) and ERR of secondary leukemia. Cumulative risks were calculated using a competing risk model. RESULTS: Secondary leukemia developed in 89 patients (EAR = 10.8 per 100,000 PY, 95% confidence interval [CI] = 7.6-14.6; ERR = 1.6, 95%CI = 1.0-2.2). Statistically significantly elevated risks were observed for acute myeloid leukemia (AML) (EAR = 7.2, 95%CI = 4.7-10.2) and acute lymphoblastic leukemia (EAR = 1.3, 95%CI = 0.4-2.8). In multivariate analyses, AML risk was higher among patients whose initial management included chemotherapy compared to those receiving radiotherapy alone (p = 0.1). Excess cumulative leukemia risk was approximately 0.23% by 30 years after testicular cancer diagnosis. CONCLUSIONS: Although ERR of leukemia following testicular cancer is large, EAR and cumulative risk, which are better gauges of the population burden, are small.
Authors: L B Travis; R E Curtis; H Storm; P Hall; E Holowaty; F E Van Leeuwen; B A Kohler; E Pukkala; C F Lynch; M Andersson; K Bergfeldt; E A Clarke; T Wiklund; G Stoter; M Gospodarowicz; J Sturgeon; J F Fraumeni; J D Boice Journal: J Natl Cancer Inst Date: 1997-10-01 Impact factor: 13.506
Authors: Lois B Travis; Sophie D Fosså; Sara J Schonfeld; Mary L McMaster; Charles F Lynch; Hans Storm; Per Hall; Eric Holowaty; Aage Andersen; Eero Pukkala; Michael Andersson; Magnus Kaijser; Mary Gospodarowicz; Timo Joensuu; Randi J Cohen; John D Boice; Graça M Dores; Ethel S Gilbert Journal: J Natl Cancer Inst Date: 2005-09-21 Impact factor: 13.506
Authors: Lorenzo Richiardi; Ghislaine Scélo; Paolo Boffetta; Kari Hemminki; Eero Pukkala; Jorgen H Olsen; Elisabete Weiderpass; Elizabeth Tracey; David H Brewster; Mary L McBride; Erich V Kliewer; Jon M Tonita; Vera Pompe-Kirn; Chia Kee-Seng; Jon G Jonasson; Carmen Martos; Paul Brennan Journal: Int J Cancer Date: 2007-02-01 Impact factor: 7.396
Authors: Charles B Simone; Kevin Kramer; William P O'Meara; Justin E Bekelman; Arnaud Belard; James McDonough; John O'Connell Journal: Int J Radiat Oncol Biol Phys Date: 2011-01-13 Impact factor: 7.038
Authors: Ryan P Kopp; Michael Chevinsky; Melanie Bernstein; George Bosl; Robert Motzer; Dean Bajorin; Darren Feldman; Brett S Carver; Joel Sheinfeld Journal: Urology Date: 2016-11-02 Impact factor: 2.649
Authors: Stephen D Dertinger; Svetlana L Avlasevich; Dorothea K Torous; Jeffrey C Bemis; Souk Phonethepswath; Carson Labash; Kristine Carlson; Jared Mereness; John Cottom; James Palis; James T MacGregor Journal: Toxicol Sci Date: 2014-05-05 Impact factor: 4.849
Authors: Jane L Meisel; David M Hyman; Anjali Jotwani; Qin Zhou; Nadeem R Abu-Rustum; Alexia Iasonos; Malcolm C Pike; Carol Aghajanian Journal: Gynecol Oncol Date: 2014-12-26 Impact factor: 5.482
Authors: C Newton; K Murali; A Ahmad; H Hockings; R Graham; V Liberale; S-J Sarker; J Ledermann; D M Berney; J Shamash; S Banerjee; S Stoneham; M Lockley Journal: Eur J Cancer Date: 2019-04-04 Impact factor: 9.162